The Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Medical Scientist Training Program, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
The Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Cell Rep Med. 2024 May 21;5(5):101518. doi: 10.1016/j.xcrm.2024.101518. Epub 2024 Apr 19.
Population-based genomic screening may help diagnose individuals with disease-risk variants. Here, we perform a genome-first evaluation for nine disorders in 29,039 participants with linked exome sequences and electronic health records (EHRs). We identify 614 individuals with 303 pathogenic/likely pathogenic or predicted loss-of-function (P/LP/LoF) variants, yielding 644 observations; 487 observations (76%) lack a corresponding clinical diagnosis in the EHR. Upon further investigation, 75 clinically undiagnosed observations (15%) have evidence of symptomatic untreated disease, including familial hypercholesterolemia (3 of 6 [50%] undiagnosed observations with disease evidence) and breast cancer (23 of 106 [22%]). These genetic findings enable targeted phenotyping that reveals new diagnoses in previously undiagnosed individuals. Disease yield is greater with variants in penetrant genes for which disease is observed in carriers in an independent cohort. The prevalence of P/LP/LoF variants exceeds that of clinical diagnoses, and some clinically undiagnosed carriers are discovered to have disease. These results highlight the potential of population-based genomic screening.
基于人群的基因组筛查可能有助于诊断具有疾病风险变异的个体。在这里,我们对 29039 名参与者的外显子组序列和电子健康记录(EHR)进行了首次全基因组评估,这些参与者患有 9 种疾病。我们鉴定出 614 名个体携带 303 种致病性/可能致病性或预测丧失功能(P/LP/LoF)变异,产生了 644 个观察结果;487 个观察结果(76%)在 EHR 中没有相应的临床诊断。进一步调查发现,75 个临床未诊断的观察结果(15%)有未治疗疾病的症状证据,包括家族性高胆固醇血症(6 个有疾病证据的未诊断观察结果中的 3 个[50%])和乳腺癌(106 个中有 23 个[22%])。这些遗传发现能够进行靶向表型分析,在以前未诊断的个体中发现新的诊断。在具有明显外显率的基因中,观察到携带该基因的个体患有疾病,其变体的疾病检出率更高。P/LP/LoF 变异的患病率超过了临床诊断,一些临床未诊断的携带者被发现患有疾病。这些结果突出了基于人群的基因组筛查的潜力。